F S&P 500
5,556.25 +10.25 (+0.18%) F Dow Jones
39,528.00 -22.00 (-0.06%) F Nasdaq
20,100.00 +60.50 (+0.30%) E-mini Russell 2000 Index Futur
2,066.00 +5.90 (+0.29%) Petróleo
82.01 +0.27 (+0.33%) Oro
2,337.40 +0.80 (+0.03%)
Algorae Pharmaceuticals Limited (LVCLF)
Algorae Pharmaceuticals Limited
Rialto South Tower
Level 23 525 Collins Street
Melbourne, VIC 3000
Australia
61 2 9698 5414
https://www.algoraepharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. David Richard Hainsworth | CEO & Executive Chairman | 26.58k | N/D | 1974 |
| Mr. Daya Uka B.Com., C.A. | Chief Financial Officer | 101.72k | N/D | N/D |
| Dr. Belinda Di Bartolo | Chief Operations Officer | 121.15k | N/D | N/D |
| Dr. Carolyn M. Sue A.M., B.S., Ph.D. | Member of Medical Advisory Board & Chief Medical Officer of NTCELL | 33.22k | N/D | 1963 |
| Dr. James A. Mckenna | Chief Scientific Officer | N/D | N/D | N/D |
| Ms. Leah Pieris | Company Secretary | N/D | N/D | N/D |
Descripción
Algorae Pharmaceuticals Limited, a biotechnology company, focuses on developing solutions for Parkinson's disease in Australia. It is developing NTCELL, an alginate coated capsule to target the treatment of Parkinson's disease; and AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient treatment for dementia, including Alzheimer's disease. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. The company was founded in 1987 and is based in Melbourne, Australia.
Gestión corporativa
La calificación ISS Governance QuickScore de Algorae Pharmaceuticals Limited a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
